<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045916</url>
  </required_header>
  <id_info>
    <org_study_id>#3891</org_study_id>
    <secondary_id>R01MH061609</secondary_id>
    <secondary_id>DSIR 83-ATSO</secondary_id>
    <nct_id>NCT00045916</nct_id>
  </id_info>
  <brief_title>Optimizing Electroconvulsive Therapy for Depression</brief_title>
  <official_title>Optimization of Electroconvulsive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered
      with medication for the treatment of a major depressive episode (unipolar or bipolar) and
      will compare two types of ECT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study addresses 2 issues in the optimization of ECT in patients with major depression:
      whether patients treated with ECT should receive concurrent treatment with antidepressant
      medications, and the relative efficacy and side effects of high dosage right unilateral (RUL)
      ECT compared to low dosage bilateral (BL) ECT.

      This study has 2 phases. In Phase I, patients are randomized to receive nortriptyline,
      venlafaxine (Effexor), or placebo while they simultaneously receive either high dosage RUL
      ECT or low dosage BL ECT. Patients have an electrocardiogram (EKG), a chest x-ray, medical
      and neurological examinations, and blood tests. Memory function is assessed before and after
      ECT. Whenever feasible, patients are withdrawn from all prior psychotropic medication before
      the start of ECT. ECT is administered 3 times per week to inpatients and twice a week to
      outpatients. Patients continue ECT until they are asymptomatic or until there is a plateau in
      improvement over 2 treatments.

      Patients who respond to ECT enter Phase II and add lithium to either nortriptyline or
      venlafaxine within 1-3 days of the last ECT. Clinical and side effect evaluations and blood
      level determinations are conducted weekly for the first month, every 2 weeks until Week 12,
      and every 4 weeks for the remaining 12 weeks. Following any indication of relapse, patients
      are monitored more intensively and are re-evaluated within 1 week. The neurocognitive battery
      is readministered to all patients at 2 and 6 months after the acute ECT course, regardless of
      ECT clinical outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive battery</measure>
    <time_frame>Measured at baseline and at 2 and 6 months after the acute ECT course</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical evaluations, side effect evaluations, and blood level determinations</measure>
    <time_frame>Measured weekly for the first month, every 2 weeks until Week 12, and every 4 weeks for the remaining 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Memory function</measure>
    <time_frame>Measured before and after ECT</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Depression</condition>
  <condition>Depressive Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>High dosage ECT + nortriptyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dosage ECT + venlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive venlafaxine and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dosage ECT + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage ECT + nortriptyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage ECT + venlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive venlafaxine and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage ECT + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High dosage electroconvulsive therapy</intervention_name>
    <description>Participants will receive high dosage right unilateral ECT at six times the seizure threshold.</description>
    <arm_group_label>High dosage ECT + nortriptyline</arm_group_label>
    <arm_group_label>High dosage ECT + venlafaxine</arm_group_label>
    <arm_group_label>High dosage ECT + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nortriptyline</intervention_name>
    <description>Participants will receive nortriptyline.</description>
    <arm_group_label>High dosage ECT + nortriptyline</arm_group_label>
    <arm_group_label>Low dosage ECT + nortriptyline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Participants will receive venlafaxine.</description>
    <arm_group_label>High dosage ECT + venlafaxine</arm_group_label>
    <arm_group_label>Low dosage ECT + venlafaxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>Participants will receive lithium.</description>
    <arm_group_label>High dosage ECT + nortriptyline</arm_group_label>
    <arm_group_label>High dosage ECT + venlafaxine</arm_group_label>
    <arm_group_label>High dosage ECT + placebo</arm_group_label>
    <arm_group_label>Low dosage ECT + nortriptyline</arm_group_label>
    <arm_group_label>Low dosage ECT + venlafaxine</arm_group_label>
    <arm_group_label>Low dosage ECT + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Low dosage electroconvulsive therapy</intervention_name>
    <description>Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.</description>
    <arm_group_label>Low dosage ECT + nortriptyline</arm_group_label>
    <arm_group_label>Low dosage ECT + venlafaxine</arm_group_label>
    <arm_group_label>Low dosage ECT + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depressive episode (unipolar or bipolar)

          -  Pre-ECT score of 20 or higher on Hamilton Rating Scale for Depression

          -  Able to withdraw psychotropic drugs (up to 3 mg/day lorazepam allowed)

          -  ECT indicated

        Exclusion Criteria:

          -  Schizophrenia, schizoaffective disorder, or other psychosis

          -  Amnestic disorder, dementia, or delirium

          -  Pregnancy

          -  Epilepsy

          -  Current alcohol or substance abuse or dependence

          -  CNS disease or brain injury not associated with psychotropic drug exposure

          -  ECT in the past 6 months

          -  Medical contraindication for treatment with either nortriptyline or venlafaxine,
             including allergy to amitriptyline, nortriptyline, or venlafaxine; narrow angle
             glaucoma; sinus node disease; bundle branch disease; myocardial infarction; coronary
             artery bypass or angioplasty; or angina

          -  Type I antiarrhythmic medication

          -  Supine blood pressure &gt;= 170 mmHg systolic or &gt;= 105 mmHg diastolic at 3 readings over
             2 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold A. Sackeim, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>New York State Psychiatric Institute and Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001 Mar 14;285(10):1299-307.</citation>
    <PMID>11255384</PMID>
  </reference>
  <reference>
    <citation>Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, Fitzsimons L, Moody BJ, Clark J. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000 May;57(5):425-34.</citation>
    <PMID>10807482</PMID>
  </reference>
  <reference>
    <citation>McCall WV, Reboussin DM, Weiner RD, Sackeim HA. Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry. 2000 May;57(5):438-44.</citation>
    <PMID>10807483</PMID>
  </reference>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2002</study_first_submitted>
  <study_first_submitted_qc>September 16, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2002</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electroconvulsive therapy</keyword>
  <keyword>Antidepressive Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

